A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy

non-segmental vitiligo

Achievement of T-VASI 50 (≥ 50% reduction in T-VASI from Baseline) at Week 48, Achievement of F-VASI 75 (≥ 75% reduction in F-VASI from Baseline) at Week 48

Achievement of F-VASI 50 (≥ 50% reduction in F-VASI from Baseline) at Week 48;, Achievement of F-VASI 75 (≥ 75% reduction in F-VASI from Baseline) at Week 24;, Percent change from Baseline in F-VASI at Week 24;, Percent change from Baseline in T-VASI at Week 48;, Achievement of F-VASI 90 (≥ 90% reduction in F-VASI from Baseline) at Week 48;, Achievement of VNS score of "A lot less noticeable (4)" or "No longer noticeable (5)" at Week 48;, Achievement of PaGIC-V of "Much better (1)" at Week 48., Achievement of PhGIC-V of "Much better (1)" at Week 48;

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Belgium, Bulgaria, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Slovakia, Spain